AstraZeneca's closure of its Alexion acquisition is expected to prompt an upgrade to EPS guidance, likely when the company reports results on July 29, UBS says. The acquisition is expected to add about $0.40 to the pharma company's standalone EPS guidance this year, which now stands in a range of between $4.75 and $5, says UBS. Confidence in AstraZeneca's research-and-development productivity is seen returning as a result of the acquisition and after the unhelpful Covid-19 vaccine dynamics that the company has been going through, UBS says. This should in turn boost confidence in AstraZeneca's growth profile, according to the Swiss bank.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.